Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →A patent landscape analysis of continuous glucose monitor wireless telemetry: filing trends, assignee concentration, IPC technology composition and the most-cited records through 2026.
Top-5 share = the 5 largest assignees ÷ all 110 records in scope (CR5), not the ranked leaders only.
This landscape covers 110 published records at the intersection of continuous glucose monitoring and wireless telemetry, filed between 2015 and the 2026-08-31 data cut-off. The scope is defined by IPC classes spanning diagnostic devices, body-fluid devices, neural stimulation, and wireless and data-processing networks, which means the dataset captures both the sensing side of continuous glucose monitors and the data-transport layer that carries readings off the device. Patent families, not raw document counts, are the fairer unit for reading concentration, and the assignee ranking here is built on that basis.
The representative filing below, from Dexcom and dated 2016, illustrates a recurring claim pattern in the corpus: limiting and authenticating which display devices a glucose transmitter will connect to. It sits alongside a small set of heavily cited foundational records that most later filers had to draft around.
Pick a task. Every answer cites the patents behind it.
The 110 records in scope span 2015 through the current data cut-off, with publication lag meaning the most recent year understates real filing activity.
Filings rose from 2 in 2017 to a peak of 12 in 2020, and the partial 2026 figure reflects publication lag rather than a real slowdown; a growth rate is not stated here because fewer than four complete years remain once that lag is accounted for.
A61B diagnosis-and-surgery classes appear on 68.2% of the 110 records, ahead of G16H healthcare informatics at 49.1% and A61M body-fluid devices at 38.2%; because a record can carry several IPC classes these shares add to more than 100%, and the wireless-network class H04W proper sits at 15.5%, the clearest sign that most protection covers sensing and data handling rather than the radio link itself.
Shares are the percentage of the 110 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
This page is one run against one query. Ask Eureka your own question about continuous glucose monitor wireless telemetry patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaThe present disclosure relates to a continuous glucose monitor for wirelessly transmitting data relating to glucose value to a plurality of displays. Systems and methods are disclosed for limiting the number of display devices that can connect to a continuous glucose transmitter. Security, including hashing techniques and a changing application key, is used to provide secure communications between the continuous glucose transmitter and the displays, along with techniques for authenticating multiple displays and coordinating commands and data updates.Filed by Dexcom, Inc. in 2016 — illustrates the multi-display authentication pattern that recurs across the wider corpus.
View full record in Eureka| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | EP0880936A2 | Monitoring physical condition of a patient by telemetry | 929 |
| 2 | US20190252079A1 | System and method for decision support | 171 |
| 3 | US20160074587A1 | System and method for capturing dose information | 131 |
| 4 | US20170286638A1 | System and method for capturing dose information | 124 |
| 5 | WO2009016638A1 | Device for facilitating infusion of therapeutic fluids and sensing of bodily analytes | 123 |
| 6 | US20140313052A1 | Near Field Telemetry Link for Passing a Shared Secret to Establish a Secure Radio Frequency Communication Lin… | 101 |
| 7 | US20140066735A1 | Diabetes manager for glucose testing and continuous glucose monitoring | 101 |
| 8 | US20120259389A1 | Treatment of postprandial hyperglycemia by gastric electrical stimulation | 66 |
| 9 | WO2005101994A2 | Method and apparatus for providing sensor guard for data monitoring and detection systems | 62 |
| 10 | US9636457B2 | System and method for a drug delivery and biosensor patch | 46 |
Citation counts are drawn from a searched corpus and favour older filings; treat them as a measure of influence on later drafting, not of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →These four cards translate the raw filing and citation data into the questions a competitive-intelligence or IP team actually needs answered before choosing where to file next.
With the top five assignees controlling 69.1% of all 110 records and the top ten controlling 82.7%, most competitive risk in this field comes from a handful of large portfolios. The remaining 36 ranked companies each hold small numbers of records, forming a long tail rather than a second tier of comparable size.
A61B diagnosis-and-surgery classes appear on 68.2% of the 110 records; H04W wireless-network classes appear on only 15.5%. The wireless transport layer looks comparatively open compared with sensor and data-handling claims, though any new filing there should still be checked against this smaller but real prior-art base.
EP0880936A2, on telemetric monitoring of a patient's physical condition, carries far more citations than any other record in the corpus. High citation counts inside a searched corpus favour older filings, so this signals historical influence and a document every later filer had to draft around, not necessarily current commercial weight.
Filing rose from 2 records in 2017 to a peak of 12 in 2020. Because publication lags filing by roughly 18 months, the partial 2026 figure of 1 record should not be read as a slowdown — a growth rate is intentionally not stated here given fewer than four complete years remain once lag is factored in.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to continuous glucose monitor wireless telemetry patent landscape, with the prior art for and against each one.
| Assignee | Co-assignee | Shared families |
|---|---|---|
| Medingo Ltd. | F. Hoffmann-La Roche Ltd. | 1 |
| Medingo Ltd. | YODFAT OFER | 1 |
| Medingo Ltd. | GESCHEIT ILLAI | 1 |
| Medingo Ltd. | CHEIT IDDO M | 1 |
| THERASENSE INC | REGGIARDO CHRISTOPHER V | 1 |
Only five co-assignee pairs appear across the dataset, indicating that most protection in this field is held and defended by single entities rather than through joint development arrangements.
The figures above establish concentration and technology mix; the next questions are about specific claims, specific competitors, and specific gaps.
With 69.1% of the 110 records held by the top five assignees, a new filing or product in multi-display CGM telemetry should be checked claim-by-claim against those portfolios before design work goes further.
Run a freedom-to-operate check in EurekaG01N and G06K sit far below the density of A61B and G16H — worth a closer look before assuming the sensing and informatics space is fully closed off.
Explore white space in EurekaWith only 1 record published so far in 2026 against a 2020 peak of 12, watching how the ranking shifts as lagged filings surface will matter more than reading the current year in isolation.
Set up tracking in EurekaThe assignee ranking covers 46 companies, and the leader holds 28 of the 110 records in scope. The top five combined account for 69.1% of all 110 records, so protection in this field is heavily concentrated rather than spread evenly across many filers. Below the top ten, which together hold 82.7% of records, the ranking thins into a long tail of single- or few-filing entrants, meaning most freedom-to-operate risk comes from a small number of large portfolios rather than from many small ones.
A61B diagnosis-and-surgery classes cover 68.2% of the 110 records, and G16H healthcare informatics covers 49.1%, well ahead of H04W wireless-network claims at 15.5%. That gap indicates most patent activity is directed at what the sensor measures and how the data is processed and displayed, not at the wireless transport mechanism itself. A filer looking for open ground should look past the radio link toward sensing, calibration or informatics claims, where density is highest but also where design-around opportunities need to be found more carefully.
Records tagged to H04W, the wireless communication networks class, make up only 15.5% of the 110 records in scope, far below A61B's 68.2% and G16H's 49.1%. This suggests the transceiver and radio-protocol layer has been treated more as a commodity component than as a primary claim target, while the sensor and data-management layers carry the bulk of filed protection. Anyone designing a new CGM telemetry link should still search this class carefully, but the denser prior art sits elsewhere.
CA2962650A1, filed by Dexcom in 2016, is the most useful representative record because it directly claims a continuous glucose monitor that limits and authenticates connections to multiple display devices using hashing and a rotating application key. It illustrates the multi-display security pattern that recurs across the corpus and is a practical starting point for a freedom-to-operate check. The most-cited record overall, EP0880936A2 on telemetric patient monitoring with 929 citations, is the older foundational document worth reading second.
Not very, on its own. Publication typically lags actual filing by roughly 18 months, so the most recent year in any patent trend — 2026 here — always understates real activity, and a growth rate has not been stated because fewer than four complete years remain once that lag is accounted for. The peak year recorded so far is 2020 at 12 filings; readers should treat the years after that as provisional rather than as evidence of a slowdown.
Go past this page: query the whole continuous glucose monitor wireless telemetry patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.